Clearance of increased serum advanced glycosylation end products in patients with end stage renal disease by hemodialysis.
Clearance of increased serum advanced glycosylation end products in patients with end stage renal disease by hemodialysis.
复制标题
DOI：
--
复制
发表时间：
2000-03
影响因子：
8.2
通讯作者：
N. Liu;Z. Sun;B. Liu
中科院分区：
文献类型：
--
作者：
N. Liu;Z. Sun;B. Liu
AIM To study the effect of removal of hemodialysis using acetate membrane on serum advanced glycosylation end products (AGEP) in 36 patients (59.1 +/- 1.6) with end stage renal disease (ESRD). METHODS Serum AGEP levels were determined with quantitative fluorescence spectrometry, flow injection analysis (FIA), and competitive enzyme-linked immunosorbent assay (ELISA) using a polyclonal antibody directed against AGEP. RESULTS The serum AGEP levels in patients with ESRD quantified by fluorescence spectrometry, FIA, and ELISA were higher than those in controls [(25 +/- 5) vs (7.5 +/- 1.5), (6.1 +/- 1.8) vs (1.4 +/- 0.5), and (37 +/- 20) vs (9 +/- 10) kU/L, respectively] and markedly reduced to [(22 +/- 6), (4.2 +/- 1.4), and (19 +/- 14) kU/L, respectively] after hemodialysis. CONCLUSION Increased serum AGEP levels in the circulation of patients with ESRD were reduced effectively by hemodialysis.
